Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Synphilin-1 attenuates mutant LRRK2-induced neurodegeneration in Parkinson's disease models.

Liu J, Li T, Thomas JM, Pei Z, Jiang H, Engelender S, Ross CA, Smith WW.

Hum Mol Genet. 2016 Feb 15;25(4):672-80. doi: 10.1093/hmg/ddv504. Epub 2016 Jan 6.

PMID:
26744328
2.

Genetic Disorders with Tau Pathology: A Review of the Literature and Report of Two Patients with Tauopathy and Positive Family Histories.

Tacik P, Sanchez-Contreras M, Rademakers R, Dickson DW, Wszolek ZK.

Neurodegener Dis. 2016;16(1-2):12-21. doi: 10.1159/000440840. Epub 2015 Nov 10.

PMID:
26550830
3.

Pathways to Parkinsonism Redux: convergent pathobiological mechanisms in genetics of Parkinson's disease.

Kumaran R, Cookson MR.

Hum Mol Genet. 2015 Oct 15;24(R1):R32-44. doi: 10.1093/hmg/ddv236. Epub 2015 Jun 22. Review.

PMID:
26101198
4.

The Role of α-Synuclein and LRRK2 in Tau Phosphorylation.

Kawakami F, Ichikawa T.

Parkinsons Dis. 2015;2015:734746. doi: 10.1155/2015/734746. Epub 2015 Apr 21. Review.

5.

Saskatchewan movement disorders program.

Rajput AH, Rajput A.

Can J Neurol Sci. 2015 Mar;42(2):74-87. doi: 10.1017/cjn.2015.13.

6.

LRRK2 pathobiology in Parkinson's disease.

Martin I, Kim JW, Dawson VL, Dawson TM.

J Neurochem. 2014 Dec;131(5):554-65. doi: 10.1111/jnc.12949. Epub 2014 Oct 10. Review.

7.

A novel, ultrasensitive assay for tau: potential for assessing traumatic brain injury in tissues and biofluids.

Rubenstein R, Chang B, Davies P, Wagner AK, Robertson CS, Wang KK.

J Neurotrauma. 2015 Mar 1;32(5):342-52. doi: 10.1089/neu.2014.3548. Epub 2014 Dec 23.

8.

Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration.

Tsika E, Kannan M, Foo CS, Dikeman D, Glauser L, Gellhaar S, Galter D, Knott GW, Dawson TM, Dawson VL, Moore DJ.

Neurobiol Dis. 2014 Nov;71:345-58. doi: 10.1016/j.nbd.2014.08.027. Epub 2014 Aug 29.

9.

Genetics and genomics of Parkinson's disease.

Lin MK, Farrer MJ.

Genome Med. 2014 Jun 30;6(6):48. doi: 10.1186/gm566. eCollection 2014. Review.

10.

Protein phosphorylation in neurodegeneration: friend or foe?

Tenreiro S, Eckermann K, Outeiro TF.

Front Mol Neurosci. 2014 May 13;7:42. doi: 10.3389/fnmol.2014.00042. eCollection 2014. Review.

11.

LRRK2 as a Potential Genetic Modifier of Synucleinopathies: Interlacing the Two Major Genetic Factors of Parkinson's Disease.

Hyun CH, Yoon CY, Lee HJ, Lee SJ.

Exp Neurobiol. 2013 Dec;22(4):249-57. doi: 10.5607/en.2013.22.4.249. Epub 2013 Dec 31. Review.

12.

The regulation and deregulation of Wnt signaling by PARK genes in health and disease.

Berwick DC, Harvey K.

J Mol Cell Biol. 2014 Feb;6(1):3-12. doi: 10.1093/jmcb/mjt037. Epub 2013 Oct 9. Review.

13.

LRRK2 phosphorylates novel tau epitopes and promotes tauopathy.

Bailey RM, Covy JP, Melrose HL, Rousseau L, Watkinson R, Knight J, Miles S, Farrer MJ, Dickson DW, Giasson BI, Lewis J.

Acta Neuropathol. 2013 Dec;126(6):809-27. doi: 10.1007/s00401-013-1188-4. Epub 2013 Oct 11.

14.

Contribution of GTPase activity to LRRK2-associated Parkinson disease.

Tsika E, Moore DJ.

Small GTPases. 2013 Jul-Sep;4(3):164-70. doi: 10.4161/sgtp.25130. Epub 2013 Jun 10. Review.

15.

Parkinson's disease--the debate on the clinical phenomenology, aetiology, pathology and pathogenesis.

Jenner P, Morris HR, Robbins TW, Goedert M, Hardy J, Ben-Shlomo Y, Bolam P, Burn D, Hindle JV, Brooks D.

J Parkinsons Dis. 2013;3(1):1-11. doi: 10.3233/JPD-130175. Review.

16.

Exome sequencing in familial corticobasal degeneration.

Fekete R, Bainbridge M, Baizabal-Carvallo JF, Rivera A, Miller B, Du P, Kholodovych V, Powell S, Ondo W.

Parkinsonism Relat Disord. 2013 Nov;19(11):1049-52. doi: 10.1016/j.parkreldis.2013.06.016. Epub 2013 Jul 16.

17.

LRRK2: an éminence grise of Wnt-mediated neurogenesis?

Berwick DC, Harvey K.

Front Cell Neurosci. 2013 May 31;7:82. doi: 10.3389/fncel.2013.00082. eCollection 2013.

18.

Expression analysis of Lrrk1, Lrrk2 and Lrrk2 splice variants in mice.

Giesert F, Hofmann A, Bürger A, Zerle J, Kloos K, Hafen U, Ernst L, Zhang J, Vogt-Weisenhorn DM, Wurst W.

PLoS One. 2013 May 10;8(5):e63778. doi: 10.1371/journal.pone.0063778. Print 2013.

19.

TDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPT.

Ling H, Kara E, Bandopadhyay R, Hardy J, Holton J, Xiromerisiou G, Lees A, Houlden H, Revesz T.

Neurobiol Aging. 2013 Dec;34(12):2889.e5-9. doi: 10.1016/j.neurobiolaging.2013.04.011. Epub 2013 May 9. Review.

20.

α-Synuclein oligomers and clinical implications for Parkinson disease.

Kalia LV, Kalia SK, McLean PJ, Lozano AM, Lang AE.

Ann Neurol. 2013 Feb;73(2):155-69. doi: 10.1002/ana.23746. Epub 2012 Dec 7. Review.

Items per page

Supplemental Content

Write to the Help Desk